Biden kicks off initiative with promise to supply 500 million doses of Pfizer vaccine to poorer countries through COVAX program.
Management said the relatively weak results are the result of more normal business activity and less remote work, which is hurting the freelance market. This is a short-term hit to Fiverr, and it makes sense the stock is down big given the fact the company has a market cap of $6.3 billion and expects revenue of just $280 million to $288 million this year.
Yahoo Finance's Jared Blikre breaks down Novavax's latest earnings report as well as the company's latest vaccine research.
As the trading day winds to a close here at 3:45 p.m. EDT, shares of Carnival Corporation (NYSE: CCL) stock are up 6.9% over yesterday's close, and rival Norwegian Cruise Line Holdings (NYSE: NCLH) is close behind with a 6.3% gain. Investors in both these cruise line stocks, however, may owe their good fortune to a third: Royal Caribbean (NYSE: RCL). In case you haven't heard, Royal Caribbean reported its fiscal Q2 earnings results yesterday.
Reconnaissance Energy Africa Ltd. (the "Company" or "ReconAfrica") (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) and its joint venture partner NAMCOR (the state oil company of Namibia) are pleased to provide, based on the mud logging report and geochemical analysis, more comprehensive data confirming a working conventional petroleum system. The Company also reports on additional drilling results and plans for the next phase of exploration in the Kavango Basin, NE Namibia and NW Botswana.
Like other biotechs without any revenue, its value proposition to shareholders is contingent on the success of its clinical trials. The company's drug, simufilam, recently completed its phase 2 clinical trials, and the company plans to start phase 3 before the end of 2021. On July 29, Cassava reported a packet of data showing that simufilam improved cognition, slowed the progression of Alzheimer's disease, and elicited positive changes in a smattering of biomarkers.
Shares of Maxar Technologies (NYSE: MAXR) are falling today, down by 9.7% as of of 12:45 p.m. EDT, after the company reported second-quarter results. For fiscal Q2, Maxar posted revenue of $473 million, which represented a 7.7% year-over-year increase that CEO Dan Jablonsky characterized as "solid." Earnings of $0.60 per share were down significantly from the prior-year period's $4.94 in EPS, but only because last year, Maxar sold off its MDA space business, generating a big one-time profit for the company that was impossible to repeat.
ARK Invest CEO and founder Cathie Wood doesn't like standing still. This week, she added to her positions in Robinhood Markets (NASDAQ: HOOD), PagerDuty (NYSE: PD), and UiPath (NYSE: PATH). Robinhood may seem to be a quintessential Wood stock, as the online trading platform has been disrupting the retail investing game with its zero-commission transactions and its mission to level the playing field for small investors.
Investors are reading a lot (perhaps too much) into an accounting decision made in the early days of the COVID-19 pandemic.
Historically speaking, these two data points wouldn't be considered good, but right now they're positive signs.
You should never count your blowout quarters before they hatch, and that seems to fit when it comes to Roku (NASDAQ: ROKU) this week. The pioneer in home streaming posted what seemed to be pretty spectacular numbers after Wednesday's market close.
Yahoo Finance's Jared Blikre explains why Carvana stock's after hours pop on Thursday afternoon.
What happened? Shares of pot grower Tilray (NASDAQ: TLRY) are up 4.1% to $14.54 apiece as of 10:30 a.m. EDT. On Aug. 4, Tilray's CEO Irwin Simons gave an exclusive interview to cannabis business news outlet New Cannabis Ventures.
These income stocks, with yields ranging from 2% to as high as 9.1%, can pack a punch for investors' portfolios.
This payments company serves the global iGaming industry, and it's bringing its expertise to the U.S.
The second-quarter profit was a surprise at mobile-videogame company Zynga, but shares are falling because fewer people are playing.
Novavax Inc. shares fell in the extended session Thursday after the biotech’s wider-than-expected loss on the quarter overshadowed positive results for its COVID-19 vaccine booster. Novavax (NVAX) shares fell 9% after hours, following a 5.5% gain in the regular session to close at $236.20. Revenue soared to $298 million from $35.5 million in the year-ago quarter because of services performed for the U.S. government and under Coalition for Epidemic Preparedness Innovations agreements.
Shares of coronavirus vaccine developer Novavax (NASDAQ: NVAX) are up 6.7% to $238.56 apiece as of 10:30 a.m. EDT. On Aug. 4, Novavax announced the European Commission would purchase 100 million doses of its coronavirus vaccine candidate NVX-CoV2373, with an additional option to purchase 100 million doses by the end of 2023. In clinical studies, the vaccine candidate demonstrated 89.7% to 96.4% overall efficacy in immunization, depending on the strain of the coronavirus.
Virgin Galactic reported Q2 revenue that beat expectations and announced that its ticket sales have reopened in its first earnings report since Richard Branson's flight. SPCE stock rose.
OPKO Health, Inc. (NASDAQ:OPK) a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. Their CEO has been continuously buying shares, and we were curious as to why that might be.
If you thought last month's rout for Chinese technology stocks like Alibaba (NYSE: BABA) and Tencent Holdings (OTC: TCEHY) was bad, look a little further down the market cap scale. Other Nasdaq-listed peers like Trip.com (NASDAQ: TRIP) and Bilibili (NASDAQ: BILI) lost a respective 27% and 30% of their value in July versus the Nasdaq Composite's slight gain. It's never wrong to scrutinize a heavily sold-off ticker as a prospective purchase; why pay more for a good stock when you can pay less?